The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects
| Autor: | Gerez Lisya, Jozef J.P. Nauta, A. M. Palache, I.A. de Bruijn |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Influenza vaccine
medicine.medical_treatment Solvay Pharmaceuticals Drug Delivery Systems Adjuvants Immunologic Medicine Humans Aged Aged 80 and over General Veterinary General Immunology and Microbiology Group study business.industry Immunogenicity Public Health Environmental and Occupational Health Impaired immune responses Vaccines Virosome Infectious Diseases Tolerability Vaccines Inactivated Influenza Vaccines Immunology Vaccines Subunit Molecular Medicine Viral disease Safety business Adjuvant |
| Zdroj: | Vaccine. 24(44-46) |
| ISSN: | 0264-410X |
| Popis: | Several approaches are currently being pursued in order to improve the efficacy of influenza vaccines in elderly individuals and others who have impaired immune responses to conventional influenza vaccines. There are two influenza vaccines available for elderly subjects: Fluad® (Chiron) and Invivac® (Solvay Pharmaceuticals). The present clinical study was a randomized, endpoint-blind, parallel group study in elderly subjects aged 61 years and older to investigate the safety and immunogenicity of these vaccines as compared to a standard influenza vaccine Invivac® (Solvay Pharmaceuticals). The three vaccines had similar immunogenicity results, whereas the tolerability profile of Invivac was better as compared to Fluad. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect